These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12145241)

  • 1. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.
    Elbrønd B; Jakobsen G; Larsen S; Agersø H; Jensen LB; Rolan P; Sturis J; Hatorp V; Zdravkovic M
    Diabetes Care; 2002 Aug; 25(8):1398-404. PubMed ID: 12145241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.
    Agersø H; Jensen LB; Elbrønd B; Rolan P; Zdravkovic M
    Diabetologia; 2002 Feb; 45(2):195-202. PubMed ID: 11935150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
    Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
    Agersø H; Vicini P
    Eur J Pharm Sci; 2003 Jun; 19(2-3):141-50. PubMed ID: 12791417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
    Irie S; Matsumura Y; Zdravkovic M; Jacobsen LV; Kageyama S
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):273-9. PubMed ID: 18541123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
    Barrington P; Chien JY; Tibaldi F; Showalter HD; Schneck K; Ellis B
    Diabetes Obes Metab; 2011 May; 13(5):434-8. PubMed ID: 21251179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
    Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
    Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.
    Chang AM; Jakobsen G; Sturis J; Smith MJ; Bloem CJ; An B; Galecki A; Halter JB
    Diabetes; 2003 Jul; 52(7):1786-91. PubMed ID: 12829647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
    Madsbad S; Schmitz O; Ranstam J; Jakobsen G; Matthews DR;
    Diabetes Care; 2004 Jun; 27(6):1335-42. PubMed ID: 15161785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs.
    Ribel U; Larsen MO; Rolin B; Carr RD; Wilken M; Sturis J; Westergaard L; Deacon CF; Knudsen LB
    Eur J Pharmacol; 2002 Sep; 451(2):217-25. PubMed ID: 12231394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
    Barrington P; Chien JY; Showalter HD; Schneck K; Cui S; Tibaldi F; Ellis B; Hardy TA
    Diabetes Obes Metab; 2011 May; 13(5):426-33. PubMed ID: 21251178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.
    Larsen PJ; Fledelius C; Knudsen LB; Tang-Christensen M
    Diabetes; 2001 Nov; 50(11):2530-9. PubMed ID: 11679431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects.
    Jiang J; Zhang J; Jacobsen LV; Hu P
    J Clin Pharmacol; 2011 Dec; 51(12):1620-7. PubMed ID: 21273395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
    Larsen J; Hylleberg B; Ng K; Damsbo P
    Diabetes Care; 2001 Aug; 24(8):1416-21. PubMed ID: 11473079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
    Feinglos MN; Saad MF; Pi-Sunyer FX; An B; Santiago O;
    Diabet Med; 2005 Aug; 22(8):1016-23. PubMed ID: 16026367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects.
    Tiessen RG; Castaigne JP; Dreyfus JF; Nemansky M; Kruizinga HH; van Vliet AA
    Int J Clin Pharmacol Ther; 2008 Sep; 46(9):443-52. PubMed ID: 18793574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.
    Ambery PD; Klammt S; Posch MG; Petrone M; Pu W; Rondinone C; Jermutus L; Hirshberg B
    Br J Clin Pharmacol; 2018 Oct; 84(10):2325-2335. PubMed ID: 29926478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
    Matthews JE; Stewart MW; De Boever EH; Dobbins RL; Hodge RJ; Walker SE; Holland MC; Bush MA;
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4810-7. PubMed ID: 18812476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.